tradingkey.logo
tradingkey.logo
검색

ANI Pharmaceuticals Inc

ANIP
관심 목록에 추가
83.050USD
+0.270+0.33%
종가 07/01, 16:00ET시세는 15분 지연됩니다
1.89B시가총액
20.19P/E TTM

ANI Pharmaceuticals Inc

83.050
+0.270+0.33%

자세한 내용은 ANI Pharmaceuticals Inc 회사

ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.

ANI Pharmaceuticals Inc 정보

종목 코드 ANIP
회사 이름ANI Pharmaceuticals Inc
상장일May 04, 2000
CEOLalwani (Nikhil Suresh)
직원 수897
유형Ordinary Share
회계 연도 종료May 04
주소210 Main Street West
도시BAUDETTE
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호56623
전화12186343500
웹사이트https://www.anipharmaceuticals.com/
종목 코드 ANIP
상장일May 04, 2000
CEOLalwani (Nikhil Suresh)

ANI Pharmaceuticals Inc의 회사 임원진

이름
이름/직위
직위
주식 보유
변동
Mr. Chad Gassert
Mr. Chad Gassert
Senior Vice President - Corporate Development and Strategy
Senior Vice President - Corporate Development and Strategy
311.43K
+0.42%
Mr. Nikhil Suresh Lalwani
Mr. Nikhil Suresh Lalwani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
235.27K
-23.38%
Mr. Muthusamy Shanmugam
Mr. Muthusamy Shanmugam
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
82.54K
-22.14%
Mr. Ori Gutwerg
Mr. Ori Gutwerg
Senior Vice President - Generics
Senior Vice President - Generics
58.41K
-4.75%
Ms. Krista Davis
Ms. Krista Davis
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
51.95K
-12.65%
Mr. Thomas J. (Tom) Haughey, J.D.
Mr. Thomas J. (Tom) Haughey, J.D.
Independent Director
Independent Director
38.88K
-5.14%
Mr. Patrick D. Walsh
Mr. Patrick D. Walsh
Independent Chairman of the Board
Independent Chairman of the Board
38.43K
-36.36%
Mr. Thomas Andrew (Thom) Rowland
Mr. Thomas Andrew (Thom) Rowland
Senior Vice President, Head of Established Brands
Senior Vice President, Head of Established Brands
37.39K
-1.23%
Dr. Renee P. Tannenbaum, Pharm.D.
Dr. Renee P. Tannenbaum, Pharm.D.
Independent Director
Independent Director
29.51K
+14.76%
Mr. Matthew J. (Matt) Leonard
Mr. Matthew J. (Matt) Leonard
Independent Director
Independent Director
11.22K
+38.83%
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Chad Gassert
Mr. Chad Gassert
Senior Vice President - Corporate Development and Strategy
Senior Vice President - Corporate Development and Strategy
311.43K
+0.42%
Mr. Nikhil Suresh Lalwani
Mr. Nikhil Suresh Lalwani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
235.27K
-23.38%
Mr. Muthusamy Shanmugam
Mr. Muthusamy Shanmugam
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
82.54K
-22.14%
Mr. Ori Gutwerg
Mr. Ori Gutwerg
Senior Vice President - Generics
Senior Vice President - Generics
58.41K
-4.75%
Ms. Krista Davis
Ms. Krista Davis
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
51.95K
-12.65%
Mr. Thomas J. (Tom) Haughey, J.D.
Mr. Thomas J. (Tom) Haughey, J.D.
Independent Director
Independent Director
38.88K
-5.14%

자주 묻는 질문

ANI Pharmaceuticals Inc의 상위 5대 주주는 누구인가요?

ANI Pharmaceuticals Inc의 상위 5대 주주는 다음과 같습니다: Mr. Chad Gassert

ANI Pharmaceuticals Inc(ANIP)의 주식을 보유한 기관은 몇 개입니까?

2026Q1 기준으로, ANI Pharmaceuticals Inc의 주식을 보유한 기관은 총 555곳이며, 이들이 보유한 주식의 총 가치는 약 23.15M로 전체 발행 주식의 101.74%를 차지합니다. 이는 2025Q4 대비 57726.00 증가한 수치입니다.

ANI Pharmaceuticals Inc의 최대 수익원은 무엇인가요?

2026Q1 기준, ANI Pharmaceuticals Inc의 Sales of generic pharmaceutical products 부문이 가장 높은 매출을 기록했으며, 금액은 384.11M로 전체 매출의 43.48%를 차지했습니다.